Compare Charles River Laboratories Intl. Inc (CRL) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Synopsys, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while Synopsys, Inc. trades at $509.81 (market cap $95.39B). The key difference: Synopsys, Inc. is far larger — about 6.7× Charles River Laboratories Intl. Inc's market cap, and Synopsys, Inc. is more actively traded (3,374,903 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Synopsys, Inc. for 71 Days on average.
| CRL | SNPS | |
|---|---|---|
Market Cap | $14.23B | $95.39B |
Volume | 1,176,885 | 3,374,903 |
Sector | Health | Technology |
52-Week High | $310.77 | $534.56 |
52-Week Low | $149.93 | $367.70 |
Typical Hold Time | 33 Days | 71 Days |
Enterprise Value | $17.06B | $102.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
Synopsys (SNPS) trades at $509.99, up 1.46% today, and is near its 52-week high. The stock exhibits a bullish technical trend with strong moving average support. Recent quarterly earnings have consistently beaten estimates, and the company's Investor Day in October 2026 highlighted transformative AI partnerships with OpenAI and Amazon, driving a 13% stock surge and upward revisions to long-term revenue guidance.
The outlook is positive, supported by robust analyst sentiment (93% buy ratings) and a consensus price target of $572.54. Key opportunities include AI-driven growth in chip design software and margin expansion from the Ansys acquisition. Risks involve high valuation multiples and integration execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
